Boyle M J, Connors M, Flanigan M E, Geiger S P, Ford H, Baseler M, Adelsberger J, Davey R T, Lane H C
Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
J Immunol. 1995 Jun 15;154(12):6612-23.
PBL from HIV-infected patients were engrafted into CB-17 SCID mice to develop a novel small animal model for the study of HIV pathogenesis and therapy. Engraftment was achieved in 84% of mice, with human Ig (hu-Ig) levels and total human mononuclear cell recovery by peritoneal wash similar to those in control hu-PBL-SCID mice engrafted with uninfected donor cells. The hu-Ig produced by hu-HIV/PBL-SCID mice had broad reactivity against HIV. Virus could be detected in 98% of mice by polymerase chain reaction and/or viral coculture. Viremia was first detected by quantitative polymerase chain reaction on day 7 (approximately 10,000 copies of viral RNA/ml of plasma) and persisted through day 17. Quasispecies analysis of amplified, cloned, proviral DNA of the V3 region of the env gene showed that nucleotide sequences from hu-HIV/PBL-SCID mouse peritoneal wash cells on day 17 were not significantly changed from those derived from donor PBL at the time of injection. Relative to human CD4+ T cell recovery by peritoneal wash in control hu-PBL-SCID mice (CD4 = 19 +/- 2%; n = 40), severe CD4+ lymphocyte depletion (CD4 = 5 +/- 0.5%; n = 59; p < 0.001) was observed in untreated hu-HIV/PBL-SCID mice 18 to 25 days after engraftment. Treatment with 2'-beta-fluoro-2',3'-dideoxyadenosine, a nucleoside analogue, significantly reduced CD4+ T cell depletion (CD4 = 13 +/- 1; n = 59; p < 0.001) and the frequency of virus isolation (70%; p = 0.015) in the hu-HIV/PBL-SCID model. Boosting hu-Ig levels in the mice by injection of purified donor Ig with neutralizing activity did not affect the frequency of CD4+ lymphocyte recovery or virus isolation. The administration of a mAb to TNF had minimal effects. These studies demonstrate that PBL from HIV-infected donors can engraft SCID mice; that HIV can be detected in the spleen, peritoneal wash cells, and blood of these mice; that HIV infection within the model results in rapid CD4+ T cell depletion; and that anti-retroviral therapy is effective in improving CD4+ T cell recovery and reducing the frequency of virus isolation. The hu-HIV/PBL-SCID mouse model thus represents a potentially useful model in which to study HIV pathogenesis and therapy.
将来自HIV感染患者的外周血淋巴细胞(PBL)移植到CB - 17 SCID小鼠体内,以建立一种用于研究HIV发病机制和治疗的新型小动物模型。84%的小鼠实现了移植,通过腹腔灌洗获得的人免疫球蛋白(hu - Ig)水平和总人单核细胞回收率与移植未感染供体细胞的对照hu - PBL - SCID小鼠相似。hu - HIV/PBL - SCID小鼠产生的hu - Ig对HIV具有广泛的反应性。通过聚合酶链反应和/或病毒共培养可在98%的小鼠中检测到病毒。病毒血症首先在第7天通过定量聚合酶链反应检测到(血浆中病毒RNA约为10,000拷贝/ml),并持续到第17天。对env基因V3区域扩增、克隆的前病毒DNA进行准种分析表明,第17天来自hu - HIV/PBL - SCID小鼠腹腔灌洗细胞的核苷酸序列与注射时供体PBL的序列相比无显著变化。与对照hu - PBL - SCID小鼠腹腔灌洗中人类CD4 + T细胞回收率(CD4 = 19 ± 2%;n = 40)相比,未治疗的hu - HIV/PBL - SCID小鼠在移植后18至25天观察到严重的CD4 + 淋巴细胞耗竭(CD4 = 5 ± 0.5%;n = 59;p < 0.001)。用核苷类似物2'-β-氟-2',3'-二脱氧腺苷治疗可显著减少hu - HIV/PBL - SCID模型中CD4 + T细胞的耗竭(CD4 = 13 ± 1;n = 59;p < 0.001)和病毒分离频率(70%;p = 0.015)。通过注射具有中和活性的纯化供体Ig来提高小鼠体内的hu - Ig水平,并不影响CD4 + 淋巴细胞的回收率或病毒分离频率。给予抗TNF单克隆抗体的效果最小。这些研究表明,来自HIV感染供体的PBL可移植到SCID小鼠体内;在这些小鼠的脾脏、腹腔灌洗细胞和血液中可检测到HIV;该模型中的HIV感染导致CD4 + T细胞迅速耗竭;抗逆转录病毒疗法可有效改善CD4 + T细胞的恢复并降低病毒分离频率。因此,hu - HIV/PBL - SCID小鼠模型是一种潜在有用的模型,可用于研究HIV发病机制和治疗。